Imago BioSciences, Inc. (IMGO): Price and Financial Metrics


Imago BioSciences, Inc. (IMGO): $36.01

0.01 (+0.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMGO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMGO Stock Price Chart Interactive Chart >

Price chart for IMGO

IMGO Price/Volume Stats

Current price $36.01 52-week high $36.09
Prev. close $36.00 52-week low $11.56
Day low $35.99 Volume 139,300
Day high $36.02 Avg. volume 171,367
50-day MA $29.83 Dividend yield N/A
200-day MA $19.59 Market Cap 1.22B

Imago BioSciences, Inc. (IMGO) Company Bio


Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.


IMGO Latest News Stream


Event/Time News Detail
Loading, please wait...

IMGO Latest Social Stream


Loading social stream, please wait...

View Full IMGO Social Stream

Latest IMGO News From Around the Web

Below are the latest news stories about IMAGO BIOSCIENCES INC that investors may wish to consider to help them evaluate IMGO as an investment opportunity.

5 Top Pharma Stocks of 2022 to Buy for the Long Haul

The biggest drug company blockbusters bring in billions of dollars, which is one of the reasons to consider these top Pharma stocks.

Dana Blankenhorn on InvestorPlace | January 6, 2023

Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis

REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination

Yahoo | December 20, 2022

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022

- 100% of patients treated with bomedemstat for ≥24 weeks (n=62 as of October 18, 2022) achieved a platelet count in the normal range with a median time to first normal platelet count of 10 weeks — - Of 28 patients treated with bomedemstat for 48 weeks, 89% (25/28) achieved a durable (≥12 weeks) platelet count in the normal range by week 48 - - 67% (20/30) of patients treated with bomedemstat experienced a decrease in mutant allele frequencies, including JAK2 and CALR – - All 5 patients with bas

Yahoo | December 12, 2022

Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022

- As of the data cutoff of 18 October 2022, bomedemstat demonstrated spleen volume reduction in 66% (33/50) of patients and reduction in total symptom score in 65% (17/26) of patients at 24 weeks - - No patients in this Phase 2 study of bomedemstat in advanced myelofibrosis have progressed to acute myeloid leukemia while on treatment - - The Phase 2 study of bomedemstat in advanced myelofibrosis is fully enrolled, with an investigator-sponsored Phase 2 combination study of bomedemstat and ruxoli

Yahoo | December 12, 2022

Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.

RAHWAY, N.J., December 12, 2022--Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.

Yahoo | December 12, 2022

Read More 'IMGO' Stories Here

IMGO Price Returns

1-mo 0.17%
3-mo 112.95%
6-mo 134.29%
1-year 78.09%
3-year N/A
5-year N/A
YTD 0.17%
2022 51.62%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6366 seconds.